Literature DB >> 23579918

Clinical significance of FOXP3 expression in human gliomas.

L Wang1, B Zhang, X Xu, S Zhang, X Yan, F Kong, X Feng, J Wang.   

Abstract

OBJECTIVE: Studies have demonstrated that the transcription factor forkhead box P3 (FOXP3) is expressed not only in regulatory T cells, but also in some cancer cells. This study aims to clarify whether or not FOXP3 expression occurs in human gliomas and investigate the clinical significance of this expression in gliomas.
METHODS: We detected FOXP3 protein expression in 40 glioma samples, 3 normal brain tissue samples, and 4 normal tonsil tissue samples using immunohistochemical staining and western blot. The expression of FOXP3 protein was also detected in five glioma cell lines by western blot. We also evaluated the association of FOXP3 expression with clinical pathological grades, prognosis, and recurrence.
RESULTS: Western blot analysis showed that the expression of FOXP3 protein was upregulated in high-grade glioma (HGGS) samples compared with low-grade samples. The cell line U87 showed the highest FOXP3 expression, while U373 had the lowest expression. Immunohistochemical analysis detected FOXP3 protein in 35 out of the 40 (87.5 %) glioma samples and high levels of FOXP3 were observed in 26 out of the 27 (96.3 %) high-grade gliomas samples. Statistical analysis suggested that the upregulation of FOXP3 is significantly correlated with the histologic grade of gliomas (P < 0.05) and that patients with high expression of FOXP3 protein exhibit a poorer prognosis than those with low FOXP3 expression.
CONCLUSIONS: Our findings suggest that FOXP3 expression in glioma cells has a crucial function in the development of HGGS and is associated with the malignant biological behavior of HGGS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23579918     DOI: 10.1007/s12094-013-1037-x

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  20 in total

1.  Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries.

Authors:  Amy S Darefsky; Joseph T King; Robert Dubrow
Journal:  Cancer       Date:  2011-08-31       Impact factor: 6.860

2.  Foxp3 expression in p53-dependent DNA damage responses.

Authors:  Da-Jung Jung; Dong-Hoon Jin; Seung-Woo Hong; Jee-Eun Kim; Jae-Sik Shin; Daejin Kim; Byung-Joo Cho; Young-Il Hwang; Jae-Seung Kang; Wang-Jae Lee
Journal:  J Biol Chem       Date:  2010-01-14       Impact factor: 5.157

3.  Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer.

Authors:  Sebastian Hinz; Laia Pagerols-Raluy; Hans-Heinrich Oberg; Ole Ammerpohl; Sandra Grüssel; Bence Sipos; Robert Grützmann; Christian Pilarsky; Hendrik Ungefroren; Hans-Detlev Saeger; Günter Klöppel; Dieter Kabelitz; Holger Kalthoff
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 12.701

4.  The transcription factor Forkhead box P3 (FoxP3) is expressed in glioma cells and associated with increased apoptosis.

Authors:  Janka Held-Feindt; Kirsten Hattermann; Susanne Sebens; Stefan Krautwald; H Maximilian Mehdorn; Rolf Mentlein
Journal:  Exp Cell Res       Date:  2012-12-01       Impact factor: 3.905

5.  FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2.

Authors:  Tao Zuo; Runhua Liu; Huiming Zhang; Xing Chang; Yan Liu; Lizhong Wang; Pan Zheng; Yang Liu
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

6.  MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.

Authors:  J Sadones; A Michotte; P Veld; C Chaskis; R Sciot; J Menten; E J R Joossens; T Strauven; L A D'Hondt; D Sartenaer; S F E H Califice; K Bierau; C Svensson; J De Grève; B Neyns
Journal:  Eur J Cancer       Date:  2008-10-20       Impact factor: 9.162

7.  Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate.

Authors:  Lizhong Wang; Runhua Liu; Weiquan Li; Chong Chen; Hiroto Katoh; Guo-Yun Chen; Beth McNally; Lin Lin; Penghui Zhou; Tao Zuo; Kathleen A Cooney; Yang Liu; Pan Zheng
Journal:  Cancer Cell       Date:  2009-10-06       Impact factor: 31.743

8.  Foxp3 expression is associated with aggressiveness in differentiated thyroid carcinomas.

Authors:  Lucas Leite Cunha; Elaine Cristina Morari; Suely Nonogaki; Fernando Augusto Soares; José Vassallo; Laura Sterian Ward
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

9.  FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene.

Authors:  Tao Zuo; Lizhong Wang; Carl Morrison; Xing Chang; Huiming Zhang; Weiquan Li; Yan Liu; Yin Wang; Xingluo Liu; Michael W Y Chan; Jin-Qing Liu; Richard Love; Chang-Gong Liu; Virginia Godfrey; Rulong Shen; Tim H-M Huang; Tianyu Yang; Bae Keun Park; Cun-Yu Wang; Pan Zheng; Yang Liu
Journal:  Cell       Date:  2007-06-14       Impact factor: 41.582

10.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

View more
  10 in total

1.  Prognostic and microRNA profile analysis for CD44 positive expression pediatric posterior fossa ependymoma.

Authors:  C Shu; Q Wang; X Yan; J Wang
Journal:  Clin Transl Oncol       Date:  2018-04-27       Impact factor: 3.405

2.  Endogenous FOXP3 inhibits cell proliferation, migration and invasion in glioma cells.

Authors:  Biao Zhang; Yuchao Dou; Xinnv Xu; Xiuyu Wang; Bin Xu; Jixiang Du; Qiong Wang; Qingguo Li; Jinhuan Wang
Journal:  Int J Clin Exp Med       Date:  2015-02-15

3.  IPEX Syndrome, FOXP3 and Cancer.

Authors:  Runhua Liu; Silin Li; Wei-Hsiung Yang; Lizhong Wang
Journal:  J Syndr       Date:  2013-06

4.  Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma.

Authors:  Elias J Sayour; Pat McLendon; Roger McLendon; Gabriel De Leon; Renee Reynolds; Jesse Kresak; John H Sampson; Duane A Mitchell
Journal:  Cancer Immunol Immunother       Date:  2015-01-03       Impact factor: 6.968

5.  Proteomic analysis of differentially expressed proteins in 5-fluorouracil-treated human breast cancer MCF-7 cells.

Authors:  J Cai; S Chen; W Zhang; Y Wei; J Lu; J Xing; Y Dong
Journal:  Clin Transl Oncol       Date:  2013-11-12       Impact factor: 3.405

Review 6.  Immunogenetics of glioblastoma: the future of personalized patient management.

Authors:  Malak Abedalthagafi; Duna Barakeh; Kara M Foshay
Journal:  NPJ Precis Oncol       Date:  2018-12-04

Review 7.  Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites.

Authors:  Powell Perng; Michael Lim
Journal:  Front Oncol       Date:  2015-07-06       Impact factor: 6.244

8.  The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma.

Authors:  Qi Yue; Xin Zhang; Hong-Xing Ye; Yin Wang; Zun-Guo Du; Yu Yao; Ying Mao
Journal:  J Neurooncol       Date:  2013-11-26       Impact factor: 4.130

9.  Bioactive compounds from the roots of Asiasarum heterotropoides.

Authors:  Jun Lee; You Jin Lee; Se-Mi Oh; Jin-Mu Yi; No Soo Kim; Ok-Sun Bang
Journal:  Molecules       Date:  2013-12-23       Impact factor: 4.411

Review 10.  Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma.

Authors:  Jason Adhikaree; Julia Moreno-Vicente; Aanchal Preet Kaur; Andrew Mark Jackson; Poulam M Patel
Journal:  Cells       Date:  2020-01-21       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.